

ScinoPharm Taiwan, Ltd.
Notice of 2026 Annual General Shareholders' Meeting
(Summary Translation)

The 2026 Annual General Shareholders' Meeting (the "Meeting") of ScinoPharm Taiwan, Ltd. (the "Company") will be convened at 10:00 a.m., Wednesday, May 27, 2026 at ScinoPharm Taiwan, Ltd. (1 Nan-Ke 8th Road, Southern Taiwan Science Park, Shan-Hua, Tainan, Taiwan).

Convene Format: Physical Shareholders' Meeting

1. The agenda for the Meeting is as follows:

I. Report Items

- (1) 2025 Business Report.
- (2) Audit Committee's Review Report on 2025 Financial Results.
- (3) 2025 Remuneration for Employees and Directors.

II. Ratification Items

- (1) Ratification of 2025 Business Report and Financial Statements.
- (2) Ratification of the Proposed Distribution of 2025 Earnings.

III. Discussion Items

- (1) Proposed Amendments to the Articles of Incorporation of the Company.
- (2) Proposed Amendments to the Operational Procedures for Acquisition and Dispose of Assets of the Company.
- (3) Proposed release the Directors (including Independent Directors) and their representatives from non-competition restrictions.

IV. Extemporaneous motions

2. Proposal for distribution of 2025 profits has been resolved by the Board of Directors as follows:

Proposed cash dividend is NT\$229,314,375, which is equivalent to NT\$0.29 per share. Upon the approval of Annual General Shareholders' Meeting, it is proposed that the Board of Directors be authorized to resolve the distribution record date.

3. Pursuant to Article 165 of the Company Act, the Company hereby closes the share transfer registration from March 29 2026 to May 27, 2026.

4. If any shareholder solicits for a proxy, the Company will disclose the summarization of the solicitation prepared by the Company on the website of the Securities and Futures Institute (<http://free.sfi.org.tw>) on April 24, 2026. If any investor wishes to make inquiries, please log into the "free inquiry system for published information of proxy" on the website, and click the right side "entrance to published information of proxy" and input the key words for the inquiry.

5. The shareholder's voting power of this annual shareholders' meeting may be exercised by way of electronic transmission, and the exercising period will be from April 25, 2026 through May 24, 2026. Please log in the "Stockvote" established by Taiwan Depository & Clearing Corporation at <https://stockservices.tdcc.com.tw>.
6. The institution for tallying and verifying proxy forms of 2026 general shareholders' meeting is Stock Registration Department, President Securities Corporation.
7. The main contents of the general shareholders' meeting listed in the meeting notice, pursuant to Article 172 of the Company Act, will also be uploaded on the website, Market Observation Post System (TWSE MOPS)(<https://emops.twse.com.tw>). Please access and select "Shareholders' meetings" under the "Electronics Books" tab, enter the Stock code "1789" and Year "2026", and then select the "Meeting Handbook" of Shareholders' Information to query.

Board of Directors
ScinoPharm Taiwan, Ltd.